文献速递银屑病与炎症性皮肤病皮肤感染

银屑病患者使用生物制剂后带状疱疹与疱疹后神经痛风险:基于目标试验模拟的全国性研究

Risk of herpes zoster and postherpetic neuralgia in patients with psoriasis treated with biologics: a nationwide study using a target trial emulation framework.
PubMed 文献 · Br J Dermatol · 2025-01-01

该回顾性队列研究利用台湾全民健康保险研究数据库(2011-2021年),纳入接受生物制剂或传统系统治疗至少6个月的银屑病或银屑病关节炎患者(年龄≥20岁),比较不同生物制剂与TSTs的HZ和PHN风险。结果显示,阿达木单抗的HZ风险显著高于TSTs(加权HR 1.63,95%CI 1.22-2.18),而乌司奴单抗和古塞奇尤单抗的HZ风险呈降低趋势,乌司奴单抗还降低PHN风险(HR 0.22,95%CI 0.08-0.64)。

要点

  • 阿达木单抗较传统系统治疗显著增加带状疱疹风险(加权HR 1.63)。
  • 乌司奴单抗和古塞奇尤单抗的带状疱疹风险呈降低趋势。
  • 乌司奴单抗与疱疹后神经痛风险降低相关(HR 0.22)。

核心结论

  • 乌司奴单抗和古塞奇尤单抗相比传统系统治疗可能降低银屑病患者带状疱疹和疱疹后神经痛风险。
  • 阿达木单抗相比传统系统治疗显著增加带状疱疹风险。

研究设计与样本

  • 回顾性队列研究,使用台湾全民健康保险研究数据库(2011-2021年)。
  • 纳入年龄≥20岁、接受生物制剂或传统系统治疗至少6个月的银屑病或银屑病关节炎患者。
  • 按个体生物制剂或传统系统治疗分类,随访至多2.5年。
  • 使用逆概率治疗加权调整协变量,Cox比例风险模型评估风险。

主要发现

  • 阿达木单抗组带状疱疹风险显著高于传统系统治疗组(加权HR 1.63,95%CI 1.22-2.18)。
  • 乌司奴单抗组带状疱疹风险趋势较低(加权HR 0.82,95%CI 0.61-1.11)。
  • 古塞奇尤单抗组带状疱疹风险趋势较低(加权HR 0.48,95%CI 0.22-1.02)。
  • 乌司奴单抗组疱疹后神经痛风险降低(HR 0.22,95%CI 0.08-0.64)。
  • 依那西普、司库奇尤单抗、伊奇珠单抗或布罗达鲁单抗与传统系统治疗相比带状疱疹风险无统计学显著差异。

关键数值与推荐

  • 阿达木单抗加权HR 1.63(95%CI 1.22-2.18)为带状疱疹风险显著增加。
  • 乌司奴单抗加权HR 0.82(95%CI 0.61-1.11)和古塞奇尤单抗加权HR 0.48(95%CI 0.22-1.02)为带状疱疹风险降低趋势。
  • 乌司奴单抗疱疹后神经痛HR 0.22(95%CI 0.08-0.64)。

临床怎么用

  • 对于银屑病患者,选择生物制剂时需考虑带状疱疹风险,阿达木单抗可能增加风险。
  • 乌司奴单抗和古塞奇尤单抗可能优先用于带状疱疹风险较高的患者。
  • 建议在使用生物制剂前接种带状疱疹疫苗。

局限性

  • 回顾性观察性研究,可能存在残余混杂。
  • 部分生物制剂样本量较小(如布罗达鲁单抗98例、古塞奇尤单抗98例)。
  • 随访时间最长2.5年,长期风险未知。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Patients with psoriasis have a higher baseline risk of herpes zoster (HZ) than the general population. This has raised concerns that tumour necrosis factor (TNF)-α inhibitor use may be associated with an increased risk of HZ. However, the risk profiles for newer biologics, including interleukin (IL)-17, IL-12/23 and IL-23 inhibitors, remain uncertain. OBJECTIVES: To compare the risks of HZ and postherpetic neuralgia (PHN) in patients with psoriasis using different biologics (ustekinumab, secukinumab, ixekizumab, guselkumab, etanercept and adalimumab) vs. traditional systemic treatments (TSTs). METHODS: We conducted a retrospective cohort study using data from Taiwan's National Health Insurance Research Database (2011-2021). We included patients with psoriasis or psoriatic arthritis aged ≥ 20 years who had been treated with biologics or TSTs for at least 6 months. We classified patients by individual biologics or TST and followed them for up to 2.5 years from drug initiation until the occurrence of outcome events or death. The primary outcome was a diagnosis of HZ. We used inverse probability of treatment weighting to adjust for covariates, including patient age, sex, comorbidities and comedications. We used Cox proportional hazards models to evaluate the risk of HZ with different biologics. RESULTS: We identified 815, 1870, 1095, 2327, 261, 303 and 98 patients with psoriasis who were taking etanercept, adalimumab, ustekinumab, secukinumab, ixekizumab, brodalumab and guselkumab, respectively. Compared with patients receiving TSTs, for those receiving ustekinumab and guselkumab the risk of HZ trended lower [ustekinumab: weighted hazard ratio (HR) 0.82, 95% confidence interval (CI) 0.61-1.11; guselkumab: weighted HR 0.48, 95% CI 0.22-1.02], while for those receiving adalimumab it was statistically significantly higher (weighted HR 1.63, 95% CI 1.22-2.18). Additionally, ustekinumab was associated with a reduced risk of PHN (HR 0.22, 95% CI 0.08-0.64). There were no statistically significant differences in the risk of HZ between TSTs and either etanercept, secukinumab, ixekizumab or brodalumab. CONCLUSIONS: Our findings suggest that ustekinumab and guselkumab may be associated with a reduced risk of HZ and PHN vs. TSTs in patients with psoriasis. This study could have significance for real-world practice. Psoriasis is an inflammatory skin condition. It affects around 2% to 3% of people globally. People with psoriasis can have itchy and painful raised patches on their skin. The development of drugs called ‘biologics’ has changed how we treat psoriasis. Some people taking biologics experience complete clearance of their psoriasis. Biologics work by suppressing the immune system. There are concerns about infections like ‘herpes zoster’ when taking biologics. Herpes zoster is also known as ‘shingles’. Shingles results when the virus that causes chickenpox reactivates. As well as skin infections, shingles can cause nerve pain. Other complications include specific eye and brain infections. Giving patients the shingles vaccine before they take biologics is important. We investigated the link between shingles and biologics in people with psoriasis. The biologics studied were ustekinumab, secukinumab, ixekizumab, guselkumab, etanercept and adalimumab. We used a national database in Taiwan to compare patients with psoriasis taking biologics to those on other treatment. The database covers 99% of Taiwan's population (approximately 23 million people). Patients on adalimumab were at higher risk of shingles than people on other treatment. People on ustekinumab or guselkumab were at less risk of shingles and nerve pain. Some biologics may lower the risk of shingles and nerve pain versus other treatments. This could be important for treating people with psoriasis.

来源:Br J Dermatol,查看原文。版权归原作者所有。

引用

  1. Lee CN, Hsieh MH, Chen CY, et al. Risk of herpes zoster and postherpetic neuralgia in patients with psoriasis treated with biologics: a nationwide study using a target trial emulation framework. Br J Dermatol. 2025. PMID: 40112174. doi:10.1093/bjd/ljaf101

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。